Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
| FLOWERS FOOD | FLO | 4.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Johnson & Johnson’s (JNJ) Janssen Biotech, Inc. recently entered into a licensing agreement with Astellas Pharma Inc. for the latter’s Janus kinase (JAK) inhibitor, ASP015K. The collaboration is for the global (excluding Japan) development and commercialization of the candidate.
ASP015K is being developed for the once daily oral treatment of moderate-to-severe rheumatoid arthritis - three phase IIb studies are ongoing in the US/Europe and Japan. Results from a 6-week phase IIa proof of concept study conducted in psoriasis patients showed that ASP015K was well tolerated. Moreover, dose-dependent improvements in Psoriasis Areas Severity Index (PASI) change from baseline were observed.
Terms of the Deal
Per the terms of the agreement, Janssen will develop and commercialize ASP015K across the world, excluding Japan, for immune-mediated inflammatory diseases. Besides making an upfront payment of $65 million to Astellas, Janssen will make payments up to $880 million on the achievement of development and commercialization milestones. Janssen will also pay double-digit royalty to Astellas on sales.
While Astellas is responsible for the completion of the ongoing phase IIb studies, future development, clinical and regulatory activities will be handled by Janssen in its territories. Astellas will remain responsible for all these activities in Japan.
Our Take
Through this deal, Astellas is gaining a suitable partner in Johnson & Johnson, which has a strong presence in the autoimmune disease market. The autoimmune disease market represents huge commercial potential and a once-daily oral formulation would provide patients with a convenient treatment option.
Meanwhile, Johnson & Johnson is looking to strengthen its presence further in the autoimmune disease market. Besides collaborating for the development of ASP015K, the company has a collaboration agreement with GlaxoSmithKline ( GSK - Analyst Report ) for sirukumab. Sirukumab is in a phase III program for rheumatoid arthritis in adults. Johnson & Johnson has two products in its portfolio for rheumatoid arthritis – Remicade and Simponi.
We currently have a Neutral recommendation on Johnson & Johnson, which carries a Zacks #2 Rank (short-term ‘Buy’ rating).
Read the full reports :
Analyst Report on GSK